Paclitaxel, a diterpenoid derived from the needles and bark of the Pacific yew tree, is a potent inhibitor of cell replication, blocking cells in the late G 2 -mitotic phase of the cell cycle by stabilizing the microtuble cytoskeleton. Clinical trials have shown that paclitaxel has antineoplastic activity, particularly against primary epithelial ovarian carcinoma, breast cancer, colon, head and neck cancers and non-small cell lung cancer.1) Paclitaxel is a hydrophobic molecule and poorly soluble in water, for which reason it is solubilized in a 50 : 50 mixture of Cremophor EL (a polyethoxylated castor oil) and ethanol. Cremophor EL is associated with a number of side effect, including hypersensitivity, nephrotoxicity and neurotoxicity. Furthermore, Cremophor EL dissolves phthalate plastics from commonly used polyvinyl chloride bags and intravenous infusion lines.2) The use of Cremophor EL as a vehicle also appears to alter the biochemical properties of lipoproteins, such as high-density lipoprotein; it has also been shown to mediate partially the cytotoxic activities of paclitaxel in primary cultures of tumor cells from patients.3) Although a premeditation regimen with corticosteroids and antihistamine reduces the incidence of serious hypersensitivity reactions, milder reactions have still been found to occur in 5-30% of treated patients.
3)Colloidal drug carriers such as liposomes and nanoparticles can be used to improve the therapeutics index of both established and new drugs by modifying their distribution, thus increasing their efficiency and/or reducing their toxicity. This is because the drug distribution then follows the carrier, rather than depending on the physicochemical properties of the drug.
4)Despite the promising results achieved with "first-generation" drug carrier systems, their value is limited by their distribution and, in particular, by their recognition by the mononuclear phagocyte system. The major breakthrough, however, was the use of surfactant substituted with poly(ethylene glycol) (PEG) chains with molecular weight of 1000-5000.5) This provides a "cloud" of hydrophilic chains at the particle surface, which repels plasma protein. Such "sterically stabilized" particles have been shown to have circulating half lives longer than the conventional solid lipid nanoparticles (SLNs).6) This prolongation is almost independent of the injected dose and of particle diameter of 50-300 nm. Thus they can function as reservoir systems and penetrate into accessible sites, such as tumors, other than mononuclear systems.Stearic acid is a type of native physiologic molecule. It is bioacceptable and biodegradable in the human body, and thus is a good carrier material. Brij78 (polyoxyethylene 20 stearyl ether) is a nonion surfactant. Its hydrophilic end is a chain of PEG; and its hydrophobic end is stearyl alcohol. PEG-DSPE is a phospholipid substituted with PEG. The aim of this study is to prepare surface-modified long-circulating stearic acid nanoparticles containing paclitaxel, and compare two PEGylated na...